Arte Inc

NEW JERSEY CHARTER SCHOOLS PROGRAM STATE ENTITIES GRANT (PROJECT CULTIVATE 38)

HEALTH CENTER CLUSTER

HEALTH CENTER CLUSTER

GREAT SCHOOLS COLORADO CSP PROJECT

NEW MEXICO CHARTER SCHOOLS PROGRAM GRANT PROJECT

PENNSYLVANIA CSP GRANT PROGRAM

GROWING HIGH QUALITY CHARTER SCHOOLS

WASHINGTON INNOVATION AND EXCELLENCE CSP GRANT PROGRAM

FUND FOR HIGH-POTENTIAL AND UNDERSERVED CHARTER SCHOOLS

PRESCHOOL DEVELOPMENT GRANTS - DEVELOPMENT

UTAH CHARTER SCHOOLS PROGRAM (UCSP) GRANT PROJECT

ILLINOIS IMPACT INITIATIVE: CREATING AND EXPANDING HIGH-QUALITY EDUCATIONAL OPPORTUNITIES FOR ILLINOIS’ MOST UNDERSERVED STUDENTS AND COMMUNITIES.

GREAT SCHOOLS FOR CONNECTICUT CSP PROEJCT

GH/HIDN/ID 936-3100 AAD

GAINING EARLY AWARENESS AND READINESS FOR UNDERGRADUATE PROGRAMS (GEAR UP PARTNERSHIP)

SECURING SUCCESS FOR ALL NEW YORK CITY CHILDREN

THE MARYLAND MOMENTUM PROJECT IS SUBMITTED TO CONTINUE THE GROWTH OF HIGH-QUALITY CHARTER SCHOOLS ACROSS THE STATE OF MARYLAND.

ARRA - FACILITY INVESTMENT PROGRAM

DESCRIPTION:THIS ACTION PROVIDES PARTIAL FUNDING IN THE AMOUNT OF $550,000 TO SUPPORT THE STARTEX-JACKSON-WELLFORD-DUNCAN WATER DISTRICT IN SOUTH CAROLINA TO IMPLEMENT ITS PROJECT TO REPLACE THE WATER TREATMENT PLANT'S 250,000 GALLONS CLEARWELL AND 5 MILLION GALLONS (MG) RECTANGULAR CLEARWELL WITH A NEW 7.5 MILLION GALLONS (MG) PRESTRESSED CONCRETE GROUND STORAGE TANK AS DIRECTED IN THE 2024 CONSOLIDATED APPROPRIATIONS ACT OR AS IDENTIFIED IN AN APPROVED TECHNICAL CORRECTION IF ONE HAS BEEN APPROVED FOR THIS PROJECT. ACTIVITIES:THE ACTIVITIES INCLUDE THE CONSTRUCTION OF A NEW 7.5 MILLION GALLONS (MG) TANK ADJACENT TO THE EXISTING 5 MILLION GALLONS (MG) CLEARWELL NEXT TO THE MIDDLE TYGER HIGH SERVICE PUMP STATION. THE OLD 250,000 GALLONS AND 5 MILLION GALLONS (MG) CLEARWELLS WILL BE ABANDONED IN PLACE AND EVENTUALLY DEMOLISHED UPON INITIATION OF CONSTRUCTION TO REPLACE THE CONVENTIONAL TREATMENT PLANT.SUBRECIPIENT:NO SUBAWARDS ARE INCLUDED IN THIS ASSISTANCE AGREEMENT.OUTCOMES:THE ANTICIPATED DELIVERABLE INCLUDES AN INCREASE TO THE OVERALL FINISHED WATER CAPACITY NEEDS FROM 10 MILLION GALLONS (MG) TO 12.5 MILLION GALLONS (MG) AT THE STARTEX-JACKSON-WELLFORD-DUNCAN WATER DISTRICT'S WATER TREATMENT PLANT. THE EXPECTED OUTCOMES INCLUDE BECOMING MORE EFFICIENT AND COST EFFECTIVE IN OVERALL TREATMENT AND WATER PRODUCTION OPERATIONS, AND THE CONTINUED PRODUCTION OF SAFE AND RELIABLE DRINKING WATER. THE INTENDED BENEFICIARIES INCLUDE THE RESIDENTS OF THE STARTEX-JACKSON-WELLFORD-DUNCAN WATER DISTRICT IN THE STATE OF SOUTH CAROLINA.

MISSION POSSIBLE: SECURING SUCCESS FOR NYC CHILDREN

SUSTAINABLE SURVEILLANCE AT SCALE: DHIS2 AS A PLATFORM FOR IMPROVING GLOBAL CAPACITY TO PREVENT, DETECT & RESPOND TO PUBLIC HEALTH THREATS

TRIPLING ENROLLMENT IN WEST VIRGINIA'S CHARTER SECTOR IN 5 YEARS

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

TO ACHIEVE ELIMINATION OF ONCHOCERCIASIS IN THE AMERICAS, THE UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID), BUREAU FOR GLOBAL HEALTH (GH), NEGLECTED TROPICAL DISEASES DIVISION PROPOSES A COOPERATIVE AGREEMENT (CA) FOR THE CONTROL AND ELIMINATION PROJECT FOR NEGLECTED TROPICAL DISEASES, ELEMENT 3, HEREBY ACHIEVE ONCHOCERCIASIS ELIMINATION IN THE AMERICAS (ACHIEVE OEA). THE PURPOSE OF ACHIEVE OEA IS TO ONCHOCERCIASIS IN THE LAST TWO FOCI IN THE AMERICAS.

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

ASSISTANCE TO FIREFIGHTERS GRANT

INSPIRENOLA CONSORTIUM: REPLICATING HIGH QUALITY EDUCATION IN LOUISIANA

STAFFING FOR ADEQUATE FIRE AND EMERGENCY RESPONSE (SAFER)

ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING, AND MISCELLANEOUS GRANTS

TEACHER INCENTIVE FUND

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

ACCESS TO JUSTICE PROGRAM

THE PURPOSE OF THIS MOD IS TO:- - INCREMENTALLY FUND THE COOPERATIVE AGREEMENT IN THE AMOUNT OF $2,112,421.00

AWARD TO CARTER CENTER FOR INDIGENOUS CONFLICT MANAGEMENT

NEW ELECTIONS OBSERVATION ACTIVITY

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

SECURING SUCCESS FOR ALL NEW YORK CITY CHILDREN

APPLICATION PURPOSE: THE PURPOSE OF THIS GRANT IS TO CONSTRUCT AN INTERMODAL TRANSPORTATION CENTER.; ACTIVITIES PERFORMED: THIS PROJECT WILL FUND THE CONSTRUCTION OF AN INTERMODAL TRANSPORTATION BUILDING WITH THREE FULL STORIES ON APPROXIMATELY 8.67 ACRES AT ITS WATERFRONT. THE PROJECT SITE WILL INCLUDE A MIXED-USE INTERMODAL TRANSPORTATION CENTER CONSISTING OF A PASSENGER TERMINAL AND PORT AUTHORITY OFFICE SPACE. THE PROJECT SITE WILL ALSO CONNECT TO A 20-FOOT-WIDE ELEVATED PEDESTRIAN BOARDWALK FIXED PIER FLOATING DOCKS WAVE SCREEN AND HANDICAP ACCESS RAMP; EXPECTED OUTCOMES: THE CARTERET FERRY TERMINAL PROJECT IS CENTRAL TO REVITALIZING THE BOROUGHS WATERFRONT PROVIDING AFFORDABLE TRANSPORTATION AND CREATING ECONOMIC OPPORTUNITIES.; INTENDED BENEFICIARIES: CENTRAL NEW JERSEY RESIDENTS.; SUBRECIPIENT ACTIVITIES: NONE

REPLICATING ZETA'S HIGH-QUALITY CHARTER SCHOOLS

FAMILY PLANNING PROJECT INCLUDING HIV INTEGRATION TO FAMILY PLANNING SERVICES

CHARTER SCHOOLS - CHARTER SCHOOLS NATIONAL ACTIVITIES COMPETITION

FOOD FOR PROGRESS; TO PROVIDE AG COMODTYS TO DEVELOPING COUNTRIES & EMERGING DEMOCRACIES TO INTRODUCE & EXPAND FREE ENTERPRISE IN THE AG SECTOR

GRANT FOR PROD OF ADV BIOFUEL

WASTE DISPOSAL GRANTS - 09/10 STIMULUS

EARLY HEAD START

CITIZENS OF THE WORLD CHARTER SCHOOLS - LOS ANGELES GROWTH PLAN

MISSISSIPPI CHARTER SCHOOL AUTHORIZER BOARD 2017 CSP GRANT

CHARTER SCHOOLS - CHARTER SCHOOLS NATIONAL ACTIVITIES COMPETITION

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

THE ABOVE GRANT ISSUED UNDER APS M-OAA-GRO-LMA-08-279 TO CONDUCT INTERNATIONAL OBSERVATION ACTIVITIES FROM THE ESTABLISHMENT OF THE COMPREHENSIVE PEA

AMERICAN RESCUE PLAN ACT FUNDING FOR HEALTH CENTERS

HEAD START

PURPOSE: ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING/CONGRESSIONAL DIRECTED SPENDING AWARDS ARE AUTHORIZED UNDER THE CONSOLIDATED APPROPRIATIONS ACT, 2022 PUBLIC LAW 117-328 AND THE EXPLANATORY STATEMENT FOR DIVISION L OF THAT ACT. PROJECTS SELECTED FOR COMMUNITY PROJECT FUNDING/CONGRESSIONAL DIRECTED SPENDING ARE LISTED IN THE JOINT EXPLANATORY STATEMENT (JES) THAT ACCOMPANIES A SPECIFIC FISCAL YEAR’S APPROPRIATIONS ACT OR CONGRESSIONAL RECORD. THE JES LISTS PROJECT, RECIPIENT, STATE, AMOUNT AND CONGRESSIONAL SPONSOR.; ACTIVITIES TO BE PERFORMED: ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING AWARD PROJECTS INCLUDE A WIDE VARIETY OF ACTIVITIES THAT RESULT IN ECONOMIC DEVELOPMENT OR COMMUNITY DEVELOPMENT OUTCOMES. HUD WILL NOT KNOW THE FULL SCOPE OF THE PROJECT UNTIL THE RECIPIENT SUBMITS THE REQUIRED PROJECT NARRATIVE AND CONFIRMS ALIGNMENT WITH THE LANGUAGE AS PROVIDED IN THE CONGRESSIONAL RECORD. TO FIND THE DETAILS OF THE GRANT AWARD AS WRITTEN WITHIN THE CONGRESSIONAL RECORD USE THE FOLLOWING LINK AND PATH SELECTIONS TO GET TO THE DESCRIPTION OF THE ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING GRANTS HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/COMM_PLANNING/EDI-GRANTS, SELECT THE FISCAL YEAR OF INTEREST, SCROLL DOWN TO PROGRAM LAWS AND REGULATIONS, UNDER FISCAL YEAR 20XX CONSOLIDATED APPROPRIATIONS ACT, 20XX: CONGRESSIONAL RECORD (JOINT EXPLANATORY STATEMENT).; EXPECTED OUTCOMES: COMPLETION OF THE PROJECT AS DESCRIBED IN THE JOINT EXPLANATORY STATEMENT (JES) PROJECT DESCRIPTION AND SUBSEQUENT APPROVED PROJECT NARRATIVE.; INTENDED BENEFICIARIES: THE PROJECT BENEFICIARIES ARE THE INDIVIDUALS AND/OR ORGANIZATIONS THAT ARE AWARDED GRANT FUNDS OR SERVED BY THE ENTITIES THAT ARE AWARDED GRANT FUNDS AS IDENTIFIED IN THE JES RECIPIENT OR PROJECT DESCRIPTION SECTIONS.; SUBRECIPIENT ACTIVITIES: THE SUBRECIPIENT ACTIVITIES ARE UNKNOWN AT THE TIME OF AWARD.

CARTER CENTER ELECTION PROGRAM

ALL TRIBES CAREER TECHNICAL EDUCATION PROGRAM HOME

WAYNE COUNTY PROSECUTOR'S OPERATION RELENTLESS PURSUIT

FAMILY PLANNING SERVICES GRANT

IMPROVE EXISTING AIRPORT

TITLE X FAMILY PLANNING PROGRAM NON-COMPETING APPLICATION 2017-2018

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

HEAD START

HIGHER EDUCATION RELIEF FUNDS FOR STUDENTS

THE CARTER CENTER MONITORING NEPAL'S PEACE AND CONSTITUTION DRAFTING

VOLUNTARY SCHOOL CHOICE

HIGHER EDUCATION RELIEF FUNDS FOR STUDENTS

HIGHER EDUCATION RELIEF FUNDS FOR INSTITUTION

DESCRIPTION:THIS AGREEMENT PROVIDES FUNDING TO ROYAL OAK CHARTER TOWNSHIP TO IMPLEMENT ITS PROJECT TO REPLACE AGING WATER MAINS AS DIRECTED IN THE 2022, 2023, AND 2024 CONSOLIDATED APPROPRIATIONS ACTS OR AS IDENTIFIED IN AN APPROVED TECHNICAL CORRECTION IF ONE HAS BEEN APPROVED FOR THIS PROJECT. THIS PROJECT USES FUNDING APPROPRIATED FROM FY22, FY23, AND FY24.ACTIVITIES:THE ACTIVITIES TO BE PERFORMED ARE THE REPLACEMENT OF UNDERSIZED AND LEAD SERVICE LINES AND MAINS IN ROYAL OAK CHARTER TOWNSHIP.SUBRECIPIENT:NO SUBAWARDS ARE INCLUDED IN THIS ASSISTANCE AGREEMENT.OUTCOMES:THE ANTICIPATED DELIVERABLES ARE IMPROVED WATER DELIVERY, WHICH ARE EXPECTED TO LEAD TO MORE RELIABLE WATER SERVICE TO THE PEOPLE OF ROYAL OAK CHARTER TOWNSHIP.

DS-19 AIRPORT HANGAR

CHARTER SCHOOLS - CHARTER SCHOOLS NATIONAL ACTIVITIES COMPETITION

STAFFING FOR ADEQUATE FIRE AND EMERGENCY RESPONSE (SAFER)

INSTITUTIONAL PORTION COVID-19 EMERGENCY RELIEF GRANT

IMPACT AID PROGRAM, TITLE VII, SECTION 7003

NYC IN BALANCE

DESCRIPTION:THIS AGREEMENT PROVIDES FUNDING TO BERLIN CHARTER TOWNSHIP TO IMPLEMENT ITS WASTEWATER DISCHARGE LINE PROJECT AS DIRECTED IN THE 2023 CONSOLIDATED APPROPRIATIONS ACT OR AS IDENTIFIED IN AN APPROVED TECHNICAL CORRECTION IF ONE HAS BEEN APPROVED FOR THIS PROJECT. ACTIVITIES:THE ACTIVITIES TO BE PERFORMED INCLUDE THE EXECUTION AND IMPLEMENTATION OF A WASTEWATER INFRASTRUCTURE CONSTRUCTION PROJECT. WORKPLAN ACTIVITIES CONSIST OF: CONSTRUCTION OF APPROXIMATELY 12,000 LINEAL FEET OF FORCE MAIN AND APPURTENANCES, ADDITION OF ONE NEW EFFLUENT PUMP, AND RESTORATION OF AREAS DISTURBED BY CONSTRUCTION. SUBRECIPIENT:NO SUBAWARDS ARE INCLUDED IN THIS ASSISTANCE AGREEMENT.OUTCOMES:THE ANTICIPATED DELIVERABLES INCLUDE INSTALLATION OF APPROXIMATELY 12,000 LINEAL FEET OF FORCE MAIN AND ONE NEW EFFLUENT PUMP. THE EXPECTED OUTCOMES INCLUDE PROTECTING WATER QUALITY IN LAKE ERIE BY PREVENTING FAILURE OF THE FORCE MAIN, REPLACING AGING INFRASTRUCTURE, AND MAINTAINING AFFORDABLE SEWER RATES. THE INTENDED BENEFICIARIES INCLUDE RESIDENTS OF BERLIN CHARTER TOWNSHIP.

NEW YORK CITY CHARTER SCHOOL CONSORTIUM FOR SCHOOL CLIMATE TRANSFORMATION

ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING, AND MISCELLANEOUS GRANTS

INVESTING IN INNOVATION - DEVELOPMENT GRANTS

MANUFACTURING RNA-BASED CAR T CELLS TO COMBAT AUTOANTIBODY-ASSOCIATED AUTOIMMUNE DISORDERS (AAAD) - AUTOANTIBODY-ASSOCIATED AUTOIMMUNE DISEASES (AAADS) ARE DISORDERS IN WHICH DYSFUNCTIONAL PLASMA CELLS (PCS) SECRETE AUTOANTIBODIES THAT ATTACK HEALTHY TISSUE. MANY AAADS ATTACK THE NERVOUS SYSTEM, SUCH AS MYASTHENIA GRAVIS (MG), NEUROMYELITIS OPTICA, CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, LAMBERT- EATON SYNDROME, AND NECROTIZING AUTOIMMUNE MYOPATHY. THIS R44 (CLINICAL TRIAL NOT ALLOWED) WILL SUPPORT MANUFACTURING OF A NEW RNA-BASED CELL THERAPY FOR NEUROLOGICAL AAADS, AND ANALYSIS OF BIOMARKERS FROM PATIENTS WHO RECEIVED THE THERAPY. CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T) THERAPY ELIMINATES PATHOGENIC CELLS, SUCH AS PCS, BY EXPRESSING ENGINEERED CHIMERIC ANTIGEN RECEPTORS (CAR) IN T CELLS ISOLATED FROM A PATIENT; THE T CELLS ARE THEN REINFUSED TO KILL THE CAR’S TARGET. ALL APPROVED CAR T DRUGS RELY ON GENE TRANSFER BY DNA, WHICH PERMANENTLY MODIFIES THE GENOME. THIS POSES SEVERAL PROBLEMS. DNA-MODIFIED CAR-T CELLS MULTIPLY EXPONENTIALLY BECAUSE CAR DNA REPLICATES; THIS CAN CAUSE LIFE-THREATENING INFLAMMATION CALLED CYTOKINE RELEASE SYNDROME (CRS). THESE CAR-T CELLS ALSO REQUIRE PRE-TREATMENT CHEMOTHERAPY TO CREATE A NICHE FOR CELL PROLIFERATION. DNA-MODIFIED CAR-T CELLS ARE EXPENSIVE TO MAKE AND USE CLINICALLY, BECAUSE FREQUENT ADVERSE EVENTS REQUIRE CLOSE PATIENT MONITORING. THESE HURDLES HAVE LIMITED CAR-T THERAPY ONLY TO ADVANCED CANCERS. CARTESIAN THERAPEUTICS HAS DESIGNED A NEW APPROACH THAT REPLACES DNA WITH RNA TO ACHIEVE TRANSIENT, TUNABLE CAR EXPRESSION (RCAR-T). UNLIKE DNA-MODIFIED CAR T CELLS, CAR-ENCODING RNA CANNOT REPLICATE AND DECAYS IN PREDICTABLE FASHION. THUS, THE PATIENT’S EXPOSURE TO RCAR-T CELLS IS DETERMINED BY CELL DOSE. THIS AVOIDS CRS AND ELIMINATES LYMPHODEPLETING CHEMOTHERAPY. THESE ADVANCES CREATE A VERSATILE, CLINICALLY-VALIDATED MEANS TO TREAT NEUROLOGICAL AAADS. WE HAVE DEVELOPED AN RCAR-T THAT TARGETS B CELL MATURATION ANTIGEN (BCMA). THIS MARKER IS EXPRESSED ON PCS – CELLS THAT PRODUCE AUTOANTIBODIES IN AAADS. THIS THERAPY – “DESCARTES-08” – TRANSIENTLY EXPRESSES ANTI-BCMA CAR TO TARGET BCMA+ PCS AFTER INFUSION. MG IS AN AAAD IN WHICH BCMA+ PCS SECRETE AUTOANTIBODIES THAT ATTACK THE NEUROMUSCULAR JUNCTION, CAUSING SEVERE MUSCLE WEAKNESS. IN THE FIRST SUCCESSFUL PHASE 2A TRIAL OF A CELL THERAPY TO TREAT AUTOIMMUNITY (NCT04146051), DESCARTES-08 CONFERRED POTENT, SAFE, AND LONG-LASTING IMPROVEMENT IN MG PATIENTS FOR 12 MONTHS OR MORE, EVEN THOUGH TREATMENT WAS ONLY 6-WEEKS (LANCET NEUROLOGY 2023). THESE BENEFITS WERE ACHIEVED WITHOUT THE TOXICITY, INPATIENT STAYS, OR LYMPHODEPLETION NEEDED IN DNA-BASED CAR-TS. HERE WE PROPOSE KEY STEPS TO DEVELOP RCAR-T AS A NEW CELL THERAPY OPTION TO TREAT NEUROLOGICAL AAADS. THE AIMS ARE I) MANUFACTURE DESCARTES-08 PRODUCT LOTS TO COMPLETE THE PHASE 2 MG CLINICAL TRIAL, II) IDENTIFY CLINICAL CORRELATES IN PATIENT SAMPLES FROM ONGOING RANDOMIZED PLACEBO-CONTROLLED TRIAL (RCT) AND III) MANUFACTURE DESCARTES-08 LOTS FOR EXPANDED ACCESS AND BASKET TRIAL PATIENTS WITH OTHER NEUROLOGICAL AAADS. COMPLETING THESE AIMS WILL POSITION DESCARTES-08 TO BECOME THE FIRST COMMERCIAL RCAR-T PRODUCT FOR A VARIETY OF AAADS.

ONCHOCERCIASIS ELIMINATION PROGRAM FOR THE AMERICAS

A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED PHASE 1 SAD STUDY IN MALE AND FEMALE HEALTHY VOLUNTEERS TO ASSESS SAFETY, PHARMACOKINETICS, AND TRANSIENT BIOMARKER CHANGES BY THE ABCA1 AGONIST CS6253 - PROJECT SUMMARY LATE-ONSET OR SPORADIC ALZHEIMER'S DISEASE (AD) CONSTITUTE 95 PERCENT OF ALL AD AND APOE4 IS THE DOMINATING GENETIC RISK FACTOR. WHILE THERE ARE THREE MAJOR APOE ALLELIC VARIANTS (APOE2, APOE3, AND APOE4), APOE4 CARRIERS HAVE AN INCREASED RISK OF DEVELOPING AD, AND UP TO 66% OF INDIVIDUALS WITH AD-TYPE DEMENTIA CASES AND 64% WITH MILD COGNITIVE IMPAIRMENT, ALSO CARRY THE APOE4 ALLELE. THERE ARE CURRENTLY NO TREATMENTS FOR APOE4 DRIVEN AD OR OTHER DEMENTIAS. ARTERY THERAPEUTICS, INC. (ARTERY; ATI) HAS DEVELOPED A NOVEL CHEMICAL ENTITY FOR THE TREATMENT OF APOE4 DRIVEN DEMENTIAS, INCLUDING AD. CS6253 IS A 2ND-GENERATION SELECTIVE ATP- BINDING-CASSETTE A1 (ABCA1) TRANSPORTER AGONIST PEPTIDE DERIVED FROM THE C-TERMINAL OF APOE. CS6253 IS A SAFE, POTENT, AND DRUGGABLE ABCA1 AGONIST. ATI'S PRECLINICAL DATA IN CELL SYSTEMS AND TWO DIFFERENT APOE4 TRANSGENIC MICE MODELS HAVE DEMONSTRATED THAT CS6253 ENGAGES ABCA1 AS A TARGET, IMPROVES APOE LIPIDATION, PREVENTS HIPPOCAMPAL AMYLOID-SS (ASS) PATHOPHYSIOLOGY, AND IMPROVES COGNITION. IN IND-ENABLING STUDIES, WHICH SHOWED EXCELLENT SAFETY AND PHARMACOKINETICS PROPERTIES, IT WAS DEMONSTRATED THAT IN PRIMATES, CS6253 TREATMENT OVER 9 DAYS SHOWED PRONOUNCED DOSE-RESPONSE REDUCTIONS IN CEREBROSPINAL FLUID (CSF) CONCENTRATIONS OF ASS42, ASS40, AND APP, AND OTHER MARKERS. THESE DATA STRONGLY SUPPORT AND EXTEND OUR EFFICACY RESULTS IN MICE PHARMACOLOGY MODELS AND ARE PREDICTIVE OF EFFICACY IN HUMANS. THUS, WITH THIS SBIR PROPOSAL, WE WILL ADVANCE CS6253 INTO EARLY CLINICAL TRIALS. IN AIM 1, ATI WILL ESTABLISH QUALIFYING METHODS FOR GMP DRUG PRODUCT AND STABILITY AT -20C FOR COFA AND RELEASE FOR PHASE 1 CLINICAL TRIAL MATERIAL. GMP DRUG PRODUCT WILL COMPLETE THE CMC SECTION (GMP DRUG SUBSTANCE IS ALREADY PRODUCED) WHICH WILL BE ADDED TO THE CLINICAL AND NONCLINICAL SECTIONS OF THE IND, FOR SUBMITTING THE IND. THE AIM 1 MILESTONE IS TO OPEN THE IND, I.E. RECEIVE FDA BUY-IN FOR INITIATING THE CS6253 PHASE 1 TRIAL. WE ARE CONFIDENT OF A SUCCESSFUL IND BASED ON THE AUGUST 2020 PRE-IND MEETING WITH FDA WHERE CONSENSUS WAS REACHED REGARDING KEY ASPECTS OF THE PROGRAM INCLUDING CMC, NONCLINICAL AND THE INITIAL CLINICAL TRIALS. IN AIM 2, WE WILL PERFORM A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED SINGLE ASCENDING DOSE TRIAL IN HEALTHY 50-70 Y.O. MEN AND WOMEN (N=8/COHORT, 6 ACTIVE: 2 PLACEBO, TOTAL N=32) WHO WILL BE CHARACTERIZED BUT NOT STRATIFIED FOR APOE ISOFORM. PARTICIPANTS WILL RECEIVE A SINGLE INTRAVENOUS (IV) ADMINISTRATION OF CS6253 AT 4 SINGLE ASCENDING DOSES. OUR AIM 2 MILESTONE IS TO ESTABLISH SAFETY AND PHARMACOKINETICS (PLASMA AND CSF) IN HUMANS AND A SAFE STARTING DOSE FOR THE MULTIPLE ASCENDING DOSE (MAD) STUDY. WE WILL ALSO EXPLORE TRANSIENT EFFECTS ON LIPIDS AND AD BIOMARKERS BY CS6253 INCLUDING TEMPORAL PLASMA – CSF DYNAMICS OF APOLIPOPROTEINS AND AD MARKERS. THIS PROJECT WILL DETERMINE CS6253'S PHARMACOKINETICS (PLASMA AND CSF) AND SINGLE DOSE SAFETY, AND PREPARE FOR PHASE 1 MAD STUDIES OF UP TO 30 DAYS. OVERALL, CS6253 IS AN EXTREMELY PROMISING ABCA1 TARGETING NOVEL THERAPY WITH POTENTIAL TO ADDRESS APOE4 ASSOCIATED DEMENTIA INCLUDING AD.

EXPANDING SUCCESS FOR NYC CHILDREN

INCREASE PUBLIC CONFIDENCE IN THE FORMAL JUSTICE SYSTEM THROUGH OUTREACH

EARLY READING FIRST

ESCUELA DE ARTES PLASTICAS Y DISENO USDE TITLE V

CS6253 DEVELOPMENT FOR THE TREATMENT OF APOE4 DRIVEN DEMENTIA INCLUDINGALZHEIMER'S DISEASE

TAS::89 0321::TAS NEW CONGRESSIONALLY DIRECTED GRANT TO THE CHARTER TOWNSHIP OF YPSILANTI FOR A PROJECT ENTITLED "ENERGY EFFICIENCY UPGRADES FOR THE

THE NEW YORK CITY CHARTER SCHOOL CONSORTIUM TO ....

GREAT OAKS LEGACY CHARTER SCHOOL: EXPANDING HIGH-QUALITY SEATS IN NEWARK, NEW JERSEY

SCHOOL CLIMATE TRANSFORMATION GRANTS TO LEAS

IMPACT AID PROGRAM, TITLE VII, SECTION 7003

SOLAR3.0 A NATIONAL PLATFORM FOR PROCESS INNOVATION

TRI-STATE ALLIANCE FOR IMPROVING DISTRICT-LED CHARTER AUTHORIZING

ADVANCING WOMEN'S RIGHT OF ACCESS TO INFORMATION IN BANGLADESH (AWRTI) ACTIVITY.

CS6253 SEQUENTIAL SUBCUTANEOUS PHARMACOKINETIC STUDY FOLLOWED BY PHASE 2A PLACEBO-CONTROLLED TRIAL WITH THREE FIXED DOSES IN APOE4 MCI AND AD PATIENTS TO ASSESS SAFETY, PK, AND BIOMARKER EFFECTS - PROJECT SUMMARY ARTERY THERAPEUTICS, INC. (ATI) IS DEVELOPING CS6253, A HIGHLY DIFFERENTIATED, CHOLESTEROL-TRANSPORT FOCUSED TREATMENT FOR THE INDICATION OF HEREDITARY APOE4-ASSOCIATED DEMENTIA INCLUDING MCI-AD, TARGETING THE ATP- BINDING-CASSETTE-TRANSPORTER A1 (ABCA1). WE NOW PROPOSE TWO SEQUENTIAL CS6253 STUDIES TO DELINEATE MECHANISM AND SHOW PROOF OF CONCEPT (POC) IN HOMOZYGOUS APOE4 EARLY AD PATIENTS. IN THE RECENTLY PERFORMED PHASE 1 SAD-MAD STUDY IN HEALTHY MEN AND WOMEN CS6253 SHOWED FAVORABLE SAFETY/TOLERABILITY AND PHARMACOKINETICS (PK), APOE TARGET ENGAGEMENT AND AN AMYLOID-CLEARANCE SIGNAL CONSISTENT WITH PREVIOUS MOUSE MODEL (BOEHM, 2016) AND PRIMATE (NOVEIR, 2022) STUDIES. IN THE PHASE 1 STUDY WE ALSO PERFORMED AN EXPLORATORY IV-SC BIOEQUIVALENCE SUB-STUDY SHOWING THAT A SINGLE CS6253 SC BOLUS INJECTION OF 1 MG/KG WAS SAFE WITH A 79% BIOAVAILABILITY (COMPARED TO IV INJECTION) AND WITHIN THE EXPOSURE RANGE OF THE SUCCESSFUL TARGETED REPLACEMENT MICE STUDIES (BOEHM, 2016). WE NOW NEED TO SHOW THAT MULTIPLE-FOLD HIGHER EXPOSURE LEVELS CAN BE REACHED BY SC ROUTE OF ADMINISTRATION PRIOR TO COMMENCING PHASE 2A MECHANISM/PROOF OF CONCEPT (POC) STUDIES, COVERING A WIDER EXPOSURE RANGE, TO EVALUATE SAFETY, PK, AND PHARMACODYNAMICS (PD) EFFECTS. THUS, OUR OBJECTIVES ARE TO PERFORM A SUBCUTANEOUS (SC) INJECTION PK FEASIBILITY STUDY WITH THE ABCA1 AGONIST CS6253, AND PROVIDED PRESPECIFIED DRUG EXPOSURE SUCCESS CRITERIA ARE MET, THEN PERFORM A 28-DAY PHASE 2A MECHANISM/POC STUDY IN 48 APOE4-CARRIERS WITH MILD COGNITIVE IMPAIRMENT (MCI), OF WHICH HALF ARE HOMOZYGOUS, TO ASSESS SAFETY, TOLERANCE, PK, PLASMA AND CSF BIOMARKER EFFECTS. WE WILL ASSESS; 1) CS6253’S ABCA1 TARGET ENGAGEMENT BY FOLLOWING CHANGE IN CSF AND PLASMA APOE (TOTAL AND ISOMER SPECIFIC PROTEIN AND GLYCOSYLATION LEVELS) AND LIPIDATION (PRIMARY EFFECT); 2) TEST AMYLOID-CLEARANCE HYPOTHESIS BY FOLLOWING CSF AND PLASMA AΒ42, AΒ40, AΒ42/40-RATIO (SECONDARY); 3) ABCA1 CHOLESTEROL-TRANSPORT SALUTARY EFFECTS BY FOLLOWING PLASMA AND CSF CHANGES IN P-TAU 181, 217, 231, GFAP, NFL, AND TREM2 (TERTIARY); 4) EXPLORE DIRECT VS INDIRECT CS6253 EFFECT BY ASSESSING UPREGULATION OF NATURAL ABCA1 AGONISTS AS APOE AND SMALL APOA-I PARTICLES IN PLASMA AND CSF (EXPLORATORY); 5) INFORM ON OPTIMAL DOSING-REGIMEN, PATIENT POPULATION (HOMOZYGOUS VS HETEROZYGOUS) AND POWER FOR SUBSEQUENT PHASE 2-3 STUDIES (TRIAL PREPARATORY). WITH A POSITIVE OUTCOME FROM THESE IMPORTANT STUDIES IN THE APOE4 CARRIER PATIENT POPULATION THE NEXT REGULATORY- CLINICAL DEVELOPMENT STEPS ARE TO PROPOSE BREAKTHROUGH DESIGNATION WITH THE FDA AND ASSESS CS6253 EFFECTS ON COGNITION IN A PHASE 2-3, 9 MONTH RANDOMIZED CONTROLLED TRIAL (RCT) IN HOMOZYGOUS APOE4 CARRIERS WITH AD/ADRD.

EARLY READING FIRST

IMPACT AID PROGRAM, DISCRETIONARY CONSTRUCTION PROGRAM

AWARD CONDUCTS INTERNATIONAL ELECTORAL AND POLITICAL OBSERVATION TO SUPPORT A PEACEFUL DEMOCRATIC TRANSITION IN TUNISIA.

PROJECT PREVENT

CHARTER SCHOOLS - CHARTER SCHOOLS NATIONAL ACTIVITIES COMPETITION

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

SAFE SCHOOLS/HEALTHY STUDENTS GRANTS

STRENGTHENING INSTITUTIONS - HISPANIC SERVING INSTITUTIONS

NEW YORK CITY CHARTER SCHOOL CONSORTIUM FOR MENTAL HEALTH SERVICE PROFESSIONAL DEVELOPMENT GRANT PROGRAM

PURPOSE: TO PROVIDE GRANTS TO COMMUNITY DEVELOPMENT FINANCIAL INSTITUTIONS (CDFIS) FOR THE FOLLOWING PURPOSES 1) TO EXPAND LENDING, GRANT MAKING AND INVESTMENT ACTIVITIES IN LOW OR MODERATE INCOME COMMUNITIES AND TO BORROWERS THAT HAVE HISTORICALLY EXPERIENCED SIGNIFICANT UNMET CAPITAL AND FINANCIAL SERVICES NEEDS AND WERE DISPROPORTIONATELY IMPACTED BY THE COVID 19 PANDEMIC; AND 2) TO ENABLE CDFIS TO BUILD ORGANIZATIONAL CAPACITY AND ACQUIRE TECHNOLOGY, STAFF, AND OTHER TOOLS NECESSARY TO ACCOMPLISH THE ACTIVITIES UNDER A CDFI ERP AWARD. PLANNED ACTIVITIES: ELIGIBLE ACTIVITIES INCLUDE FINANCIAL PRODUCTS, FINANCIAL SERVICES, DEVELOPMENT SERVICES, GRANTS, LOAN LOSS RESERVES AND CAPITAL RESERVES THAT MAY BE USED TO MITIGATE THE IMPACT OF THE COVID 19 PANDEMIC ON UNEMPLOYMENT, CHILDCARE, HEALTHCARE, MENTAL HEALTHCARE, AFFORDABLE HOUSING, AFFORDABLE HOUSING FINANCE, SMALL BUSINESS, SMALL FARMS, BROADBAND INTERNET, AND FOOD SUFFICIENCY. IN ADDITION, TO SUPPORT CDFIS IN BUILDING THEIR CAPACITY TO RESPOND TO THE ECONOMIC IMPACT OF COVID 19, CDFI ERP AWARDS MAY BE USED FOR COMPENSATION PERSONAL SERVICES; COMPENSATION FRINGE BENEFITS; PROFESSIONAL SERVICE COSTS; TRAVEL COSTS; TRAINING AND EDUCATION COSTS; EQUIPMENT; SUPPLIES. END GOALS: EXPANDED FINANCING FOR LOW TO MODERATE INCOME COMMUNITIES AND INDIVIDUALS THAT HAVE HISTORICALLY EXPERIENCED SIGNIFICANT UNMET CAPITAL AND FINANCIAL SERVICES NEEDS AND WERE DISPROPORTIONATELY IMPACTED BY THE COVID 19 PANDEMIC INCLUDING SPECIFIC DESIGNATED COVID IMPACTED CDFI ERP ELIGIBLE GEOGRAPHIES AS AREAS THAT MAY BENEFIT FROM CDFI ERP ASSISTANCE. BENEFICIARIES: CERTIFIED CDFIS WHICH MAY BE FOR PROFIT ORGANIZATION, PRIVATE NONPROFIT INSTITUTION/ORGANIZATION, AND OTHER PRIVATE INSTITUTION/ORGANIZATION, AS DEFINED IN 12 C.F.R. 1805, AND LOW AND MODERATE INCOME INDIVIDUALS AND FAMILIES. SUBRECIPIENTS: THERE ARE NO SUBRECIPIENTS FOR THIS PROGRAM. BROADBAND: SPECIFIC ACTIVITIES RELATING TO BROADBAND USAGE ARE NOT KNOWN AT THE TIME OF AWARD. REASON/PURPOSE OF MODIFICATION: NOT APPLICABLE.

PURPOSE: TO PROVIDE GRANTS TO COMMUNITY DEVELOPMENT FINANCIAL INSTITUTIONS (CDFIS) FOR THE FOLLOWING PURPOSES 1) TO EXPAND LENDING, GRANT MAKING AND INVESTMENT ACTIVITIES IN LOW OR MODERATE INCOME COMMUNITIES AND TO BORROWERS THAT HAVE HISTORICALLY EXPERIENCED SIGNIFICANT UNMET CAPITAL AND FINANCIAL SERVICES NEEDS AND WERE DISPROPORTIONATELY IMPACTED BY THE COVID 19 PANDEMIC; AND 2) TO ENABLE CDFIS TO BUILD ORGANIZATIONAL CAPACITY AND ACQUIRE TECHNOLOGY, STAFF, AND OTHER TOOLS NECESSARY TO ACCOMPLISH THE ACTIVITIES UNDER A CDFI ERP AWARD. PLANNED ACTIVITIES: ELIGIBLE ACTIVITIES INCLUDE FINANCIAL PRODUCTS, FINANCIAL SERVICES, DEVELOPMENT SERVICES, GRANTS, LOAN LOSS RESERVES AND CAPITAL RESERVES THAT MAY BE USED TO MITIGATE THE IMPACT OF THE COVID 19 PANDEMIC ON UNEMPLOYMENT, CHILDCARE, HEALTHCARE, MENTAL HEALTHCARE, AFFORDABLE HOUSING, AFFORDABLE HOUSING FINANCE, SMALL BUSINESS, SMALL FARMS, BROADBAND INTERNET, AND FOOD SUFFICIENCY. IN ADDITION, TO SUPPORT CDFIS IN BUILDING THEIR CAPACITY TO RESPOND TO THE ECONOMIC IMPACT OF COVID 19, CDFI ERP AWARDS MAY BE USED FOR COMPENSATION PERSONAL SERVICES; COMPENSATION FRINGE BENEFITS; PROFESSIONAL SERVICE COSTS; TRAVEL COSTS; TRAINING AND EDUCATION COSTS; EQUIPMENT; SUPPLIES. END GOALS: EXPANDED FINANCING FOR LOW TO MODERATE INCOME COMMUNITIES AND INDIVIDUALS THAT HAVE HISTORICALLY EXPERIENCED SIGNIFICANT UNMET CAPITAL AND FINANCIAL SERVICES NEEDS AND WERE DISPROPORTIONATELY IMPACTED BY THE COVID 19 PANDEMIC INCLUDING SPECIFIC DESIGNATED COVID IMPACTED CDFI ERP ELIGIBLE GEOGRAPHIES AS AREAS THAT MAY BENEFIT FROM CDFI ERP ASSISTANCE. BENEFICIARIES: CERTIFIED CDFIS WHICH MAY BE FOR PROFIT ORGANIZATION, PRIVATE NONPROFIT INSTITUTION/ORGANIZATION, AND OTHER PRIVATE INSTITUTION/ORGANIZATION, AS DEFINED IN 12 C.F.R. 1805, AND LOW AND MODERATE INCOME INDIVIDUALS AND FAMILIES. SUBRECIPIENTS: THERE ARE NO SUBRECIPIENTS FOR THIS PROGRAM. BROADBAND: SPECIFIC ACTIVITIES RELATING TO BROADBAND USAGE ARE NOT KNOWN AT THE TIME OF AWARD. REASON/PURPOSE OF MODIFICATION: NOT APPLICABLE.

THERAPEUTIC POTENTIAL OF EX VIVO EXPANDED HUMAN CORD BLOOD DERIVED CD133+ CELLS I

STUDENT EMERGENCY RELIEF

MANUFACTURING OF ABCA1 AGONIST SMALL MOLECULE PEPTIDE CS6253 TO SUPPORT CHRONIC TOXICOLOGY STUDIES IN WISTAR RATS AND CYNOMOLGUS MONKEYS - PROJECT SUMMARY THE PRIMARY AIM OF THIS PROPOSAL IS TO MANUFACTURE THE ABCA1 AGONIST SMALL MOLECULE PEPTIDE CS6253 FOR UPCOMING CHRONIC TOXICOLOGY STUDIES (OUTSIDE OF THIS GRANT SCOPE) IN WISTAR RATS AND CYNOMOLGUS MONKEYS. FOLLOWING THIS, ARTERY THERAPEUTICS, INC. (ATI) PLANS TO OVERSEE THE EXECUTION OF THESE STUDIES AND THEN PROVIDE THE FDA WITH THE REPORTS INCLUDING IN SEND FORMAT. THE ULTIMATE GOAL IS TO LAY THE GROUNDWORK FOR PHASE 2-3 COGNITION TRIALS LASTING 6 MONTHS OR LONGER, FOCUSING ON PATIENTS WITH MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD). IN ADDITION TO MANUFACTURING THE MATERIAL FOR TOXICOLOGY STUDIES, THIS CAMPAIGN WILL ALSO INCLUDE LONG-TERM STABILITY TESTING. THE DATA GENERATED WILL BE UTILIZED TO UPDATE THE DRUG MASTER FILE. CS6253 HAS DEMONSTRATED ITS SAFETY, TOLERANCE AND FAVORABLE PHARMACOKINETICS (PK) IN THE CLINICAL PHASE 1 SAD-MAD-BIOEQUIVALENCE TRIAL ATI-CS-001 (GRANT 1R44AG076299, NATIONAL CLINICAL TRIAL # 05965414). FOLLOWING THESE SUCCESSFUL PHASE 1 RESULTS IT IS IMPERATIVE TO PROCEED TO COGNITION TRIALS. COGNITION TRIALS TYPICALLY SPAN 6 TO 9 MONTHS OR LONGER AND NECESSITATE A COMPREHENSIVE TOXICOLOGY PACKAGE AFFIRMING LONG-TERM SAFETY PRIOR TO TRIAL COMMENCEMENT. THE CHRONIC TOXICOLOGY STUDIES REQUIRE APPROXIMATELY 2.3 KILOGRAMS OF GOOD MANUFACTURING PRACTICES (GMP) LIKE DRUG SUBSTANCE MATERIAL. TO MEET THIS DEMAND, WE WILL ENGAGE THE SERVICES OF AMBIOPHARM, INC, OUR TRUSTED MANUFACTURER FROM PREVIOUS CS6253 DRUG SUBSTANCE CAMPAIGNS. AMBIOPHARM IS A FULL-SERVICE CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO), HAS SUCCESSFULLY PRODUCED ATI'S CS6253 NON-GMP TOXICOLOGY AND GMP CLINICAL DRUG SUBSTANCES THAT SUPPORTED THE INVESTIGATIONAL NEW DRUG (IND) APPLICATION AND THE ATI-CS-001 CLINICAL TRIAL. AMBIOPHARM CURRENTLY PRODUCES COMMERCIAL PEPTIDES UP TO MULTI-KG QUANTITIES AND HAS A QUALITY ASSURANCE SYSTEM IN PLACE FOR GMP PEPTIDES FOR CLINICAL TRIALS, AS DEMONSTRATED BY THEIR WORK WITH CS6253 AT ITS CURRENT STAGE AND WITH OTHER COMMERCIAL PEPTIDE PRODUCTS. CS6253 DRUG SUBSTANCE HAS DISPLAYED 32+ MONTHS STABILITY WHEN STORED IN -20 DEGREE C CONDITION. ALSO, THE ONGOING ICH DRUG PRODUCT STABILITY TESTING SHOWS THAT CS6253 IN SOLUTION REMAINS STABLE FOR MORE THAN 9 MONTHS IN 5 DEGREE C.

AUTOLOGOUS BONE MARROW DERIVED MONONUCLEAR CELL THERAPY FOR COMPARTMENT SYNDROME YEAR 3 AND 4.

CHARLESTON COUNTY ALONG WITH BERKELEY AND DORCHESTER COUNTY, PLANS TO IMPLEMENT A FULL CAD-TO-CAD (COMPUTER AIDED DISPATCH) TO ADDRESS POST-CRASH CARE IN OVERLAPPING JURISDICTIONAL AREAS BETWEEN THE CITY OF CHARLESTON AND THE CITY OF NORTH CHARLESTON AND BERKELEY AND DORCHESTER COUNTIES, RESPECTIVELY. THE IMPLEMENTATION OF THE CAD-TO-CAD CONNECTION IS A DEMONSTRATION ACTIVITY CONNECTED TO THE BERKELEY, CHARLESTON, DORCHESTER COUNCIL OF GOVERNMENT (BCDCOG) SAFETY ACTION PLAN.

STRENGTHENING CHARTER AUTHORIZING NATIONALLY

CHARTER SCHOOLS NATIONAL ACTIVITIES COMPETITION

ADDRESSING BOTH SIDES OF CHARTER QUALITY: IMPROVING AUTHORIZING PRACTICE + GROWING QUALITY CHARTER ORGANIZATIONS THROUGH THE DISSEMINATION OF FRAMEWORKS & SUPPORTS

FACILITATING CHARTER SCHOOLS: A PROPOSAL TO CREATE A CHARTER SCHOOL FACILITY CENTER AT THE NATIONAL ALLIANCE FOR PUBLIC CHARTER SCHOOLS

IMPACT AID PROGRAM, TITLE VII, SECTION 7003

INTERNATIONAL ELECTION OBSERVATION MISSION TO KENYA S

STREAMBANK <(>&<)> BED STABILIZATION/ DEBRIS REMOVAL FOR DSRS 47-01-24-5133-412THRU422 <(>&<)> 424, 52 SITES IN CARTER COUNTY, TN (S EPTEMBER 2024 HURRICANE HELENE).

CHARTER SCHOOLS NATIONAL ACTIVITIES COMPETITION

TUNISIAN CONSTITUENT ASSEMBLY ELECTION OBSERVATION

OBSERVING THE 2022 REFERENDUM AND PARLIAMENTARY ELECTIONS IN TUNISIA

ADVANCING WOMEN'S RIGHT OF ACCESS TO INFORMATION IN BANGLADESH

ESCUELA DE ARTES PLÁSTICAS Y DISEÑO DE PUERTO RICO EMERGENCY RELIEF FUND - INSTITUTIONAL PORTION

MITIGATING ELECTRCAL VIOLENCE THROUGH NATIONAL EARLY WARNING SYSTEMS (NEWS)

HEBREW PUBLIC SUPPORTING, REWARDING, AND GROWING EDUCATORS (HP SURGE)

HYDE LEADERHSUIP CHARTER SCHOOL-BROOKLYN INNOVATIVE APPROACHES TO LITERACY

STRENGTHENING GLOBAL HEALTH SECURITY THROUGH SURVEILLANCE, PREVENTION, AND RESPONSE WITH A FOCUS ON STRENGTHENING DATA AND HEALTH INFORMATION SYSTEMS - SEE ATTACHMENT

NEIGHBORHOOD STABILIZATION PRG

FRIENDSHIP SEEKS TO REPLICATE ITS HIGH SCHOOL CLUSTER MODEL OF FEEDER SCHOOLS FROM ITS NETWORK. ARMSTRONG, IDEAL AND WOODRIDGE WILL BE FEEDER SCHOOLS FOR THE FUTURE FRIENDSHIP COLLEGIATE WEST.

A PROPOSAL TO CREATE THE CHARTER SCHOOL COLLABORATIVE TO ACCELERATE STUDENT LEARNING IN RESPONSE TO THE COVID-19 PANDEMIC

HYDE LEADERSHIP CHARTER SCHOOL-BROOKLYN SUPPORTING POSITIVE, ASPIRATIONAL, AND RESPONSIBLE KIDS (SPARK)

ENRICH - ENGAGING NEW READERS IN A COMMUNITY OF HIGH-NEED

CHARTER SCHOOLS MANAGEMENT ORGANIZATIONS

VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS.

EDUCATING FOR EXCELLENCE: CREATING AND SUSTAINING DIVERSE AND EFFECTIVE CHARTER SCHOOL LEADERSHIP THROUGH THE DISSEMINATION OF PROGRAMS & SUPPORTS

CHARTER SCHOOLS NATIONAL ACTIVITIES COMPETITION

CAROL M. WHITE PHYSICAL EDUCATION PROGRAM

NEIGHBORHOOD STABILIZATION PRG

FULL SERVICE COMMUNITY SCHOOLS PROGRAM

ECONOMIC DEVELOPMENT INITIATIVE, COMMUNITY PROJECT FUNDING, AND MISCELLANEOUS GRANTS

THIS EDA INVESTMENT SUPPORTS THE CHARTER TOWNSHIP OF MUNDY WITH UPGRADING THE CRITICAL WATER AND ROAD INFRASTRUCTURE TO SERVE INDUSTRIAL USERS' REQUIREMENTS FOR WATER PRESSURE AND TRUCK ACCESS IN GENESEE COUNTY, MICHIGAN. THE PROJECT WORK INCLUDES UPGRADING APPROXIMATELY 800 FEET OF SANITARY SEWER, 9500 FEET OF WATER MAIN, 3175 FEET OF STORM SEWER, DRAIN EXTENSIONS AND DETENTION AREAS. ONCE COMPLETED, THE PROJECT WILL SUPPORT EXISTING MANUFACTURING BUSINESSES, ATTRACT NEW PRIVATE INVESTMENT, AND CREATE JOBS IN HEALTHCARE, MANUFACTURING, AND TECHNOLOGY SECTORS.

FINANCIAL ASSISTANCE AWARD

FINANCIAL ASSISTANCE AWARD

WATER TREATMENT PLANT

THE GRANTEE WILL DEPLOY A LONG-TERM ELECTION OBSERVATION MISSION TO ASSESS TUNISIA¿S PARLIAMENTARY AND PRESIDENTIAL ELECTIONS. RIGOROUS INDEPENDENT OBSERVATION ACTIVITIES, PAIRED WITH PRIVATE ADVOCACY AND PUBLIC REPORTING, SERVE TO SUPPORT TUNISIA¿S ELECTORAL AUTHORITIES WITH TIMELY, CONSTRUCTIVE RECOMMENDATIONS WHILE INCREASING TRANSPARENCY OF AND PUBLIC CONFIDENCE IN THE POLLS AND TABULATION PROCESSES.

PHASE 1/2A CLINICAL STUDY OF DESCARTES-30 IN ACUTE RESPIRATORY DISTRESS SYNDROME - ABSTRACT THIS APPLICATION IS TO SUPPORT A CLINICAL TRIAL OF THE FIRST MRNA ENGINEERED CELL THERAPY FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS), INCLUDING ARDS CAUSED BY COVID-19. THE FDA HAS ALREADY REVIEWED THE IND APPLICATION AND DETERMINED THAT THE STUDY MAY PROCEED. ARDS IS A SEVERE INFLAMMATORY RESPIRATORY FAILURE THAT KILLS AN ESTIMATED 80,000 AMERICANS EACH YEAR. 80% OF ARDS PATIENTS REQUIRE MECHANICAL VENTILATION. NO FDA-APPROVED THERAPIES FOR ARDS ARE AVAILABLE. ARDS MAY RESULT FROM INFECTIOUS OR NON-INFECTIOUS (E.G., TRAUMATIC OR CHEMICAL) INSULTS. COVID-19 IS CURRENTLY THE MOST COMMON CAUSE OF ARDS, AND THE VAST MAJORITY OF COVID-19 DEATHS ARE DUE TO ARDS. NEUTROPHIL EXTRACELLULAR TRAPS (NETS) DRIVE THE HYPERACTIVE INFLAMMATORY RESPONSE IN ARDS AND COVID-19, AND PRESENCE OF NETS CORRELATES STRONGLY WITH ARDS SEVERITY. NETS ARE PRODUCED BY LOCALLY-TRAFFICKED NEUTROPHILS UNDERGOING NETOSIS, A PROGRAMMED CELL DEATH WHERE THE CELLS LYSE TO SECRETE DNA DECORATED WITH INFLAMMATORY PROTEINS. LOW AMOUNTS OF NETS ARE THOUGHT TO HELP ENTRAP INFECTION, BUT HYPERACTIVATED NEUTROPHILS PRODUCE LARGE QUANTITIES OF NETS THAT CAUSE HYPOXIA AND IMMUNE THROMBI DUE TO PHYSICAL BLOCKADE OF ALVEOLI AND MICROVASCULATURE. A NET-DEGRADING THERAPY THEREFORE WOULD BE A SIGNIFICANT ADVANCE IN TREATMENT OF ARDS. DESCARTES-30 IS THE FIRST ALLOGENEIC (I.E., OFF-THE-SHELF) ENGINEERED HUMAN MESENCHYMAL STEM CELL (MSC) THERAPY SECRETING A COMBINATION OF TWO POTENT NET-DEGRADING ENZYMES. IN THIS PHASE 1/2A STUDY, THE HYPOTHESIS TO BE TESTED IS THAT DESCARTES-30 WILL BE WELL TOLERATED AND SHOW EVIDENCE OF EFFICACY IN PATIENTS WITH MODERATE TO SEVERE ARDS AND COVID- 19. AIMS ARE TO DETERMINE THE MAXIMUM TOLERATED DOSE AND EVIDENCE OF PRELIMINARY EFFICACY, DEFINE PHARMACOKINETIC PROPERTIES AND BIOLOGIC CORRELATES OF DISEASE, AND ESTABLISH A VALIDATED POTENCY ASSAY FOR USE IN LATER-STAGE CLINICAL DEVELOPMENT. THESE DATA WILL INFORM THE DESIGN OF A CONTROLLED REGISTRATION STUDY IN PATIENTS WITH MODERATE-TO-SEVERE ARDS.

AUTOLOGOUS T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED TO B-CELL MATURATION ANTIGEN (BCMA) IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (MG)

PHASE 1/2 CLINICAL STUDY OF HUMANIZED ANTI-BCMA CAR T CELLS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

CHARTER SCHOOLS NATIONAL ACTIVITIES COMPETITION